Key points are not available for this paper at this time.
This Viewpoint assesses the US Food and Drug Administration’s priority review voucher program to encourage development of drugs to treat neglected tropical diseases or rare pediatric disease and recommends improvements to the program.
Kesselheim et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: